Clinical Trial Update: Prediction of Response to Certolizumab Pegol Treatment by Functional MRI of the Brain [Phase 3]

View source ↗

Summary

Phase 3 trial update examining prediction of response to certolizumab pegol in rheumatoid arthritis using functional MRI of the brain.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Certolizumab pegol (certolizumab pegol)

Snippet

Sponsor: University of Erlangen-Nürnberg Medical School | Conditions: Rheumatoid Arthritis | Phase 3 | Status: COMPLETED